Neurocrine Historical Income Statement
| NBIX Stock | USD 140.71 0.00 0.00% |
Historical analysis of Neurocrine Biosciences income statement accounts such as Total Revenue of 2 B can show how well Neurocrine Biosciences performed in making a profits. Evaluating Neurocrine Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Neurocrine Biosciences's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Neurocrine Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neurocrine Biosciences is a good buy for the upcoming year.
Neurocrine |
About Neurocrine Income Statement Analysis
Neurocrine Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Neurocrine Biosciences shareholders. The income statement also shows Neurocrine investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Neurocrine Biosciences Income Statement Chart
Neurocrine Biosciences Income Statement is one of the three primary financial statements used for reporting Neurocrine's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Neurocrine Biosciences revenue and expense. Neurocrine Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Neurocrine Biosciences' Total Operating Expenses is fairly stable compared to the past year. Income Before Tax is likely to rise to about 348.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 38.9 M in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Neurocrine Biosciences. It is also known as Neurocrine Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Neurocrine Biosciences financial statement analysis. It represents the amount of money remaining after all of Neurocrine Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Neurocrine Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Total Operating Expenses is fairly stable compared to the past year. Income Before Tax is likely to rise to about 348.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 38.9 M in 2024.
Neurocrine Biosciences income statement Correlations
Click cells to compare fundamentals
Neurocrine Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurocrine Biosciences income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 7.5M | 8.6M | 10.9M | 15.6M | 21.3M | 22.4M | |
| Interest Expense | 32M | 32.8M | 25.8M | 7.1M | 4.6M | 7.4M | |
| Selling General Administrative | 354.1M | 433.3M | 583.3M | 752.7M | 851.6M | 894.2M | |
| Total Revenue | 788.1M | 1.0B | 1.1B | 1.5B | 1.9B | 2.0B | |
| Gross Profit | 780.7M | 1.0B | 1.1B | 1.5B | 1.8B | 1.9B | |
| Other Operating Expenses | 561.5M | 718.4M | 925.7M | 1.2B | 1.5B | 1.6B | |
| Operating Income | 219.1M | 318.9M | 196.9M | 249M | 250.9M | 263.4M | |
| Ebit | 219.1M | 318.9M | 196.9M | 249M | 394.8M | 414.5M | |
| Research Development | 200M | 275M | 328.1M | 463.8M | 565M | 593.3M | |
| Ebitda | 226.6M | 327.5M | 207.8M | 264.6M | 416.1M | 436.9M | |
| Cost Of Revenue | 7.4M | 10.1M | 14.3M | 23.2M | 39.7M | 38.9M | |
| Total Operating Expenses | 554.1M | 708.3M | 911.4M | 1.2B | 1.5B | 1.5B | |
| Income Before Tax | 46.5M | 106.7M | 101.4M | 213.9M | 332.1M | 348.7M | |
| Total Other Income Expense Net | (172.6M) | (212.2M) | (95.5M) | (35.1M) | (58.1M) | (55.2M) | |
| Net Income | 37M | 407.3M | 89.6M | 154.5M | 249.7M | 262.2M | |
| Income Tax Expense | 9.5M | (300.6M) | 11.8M | 59.4M | 82.4M | 86.5M | |
| Net Income From Continuing Ops | 37.0M | 407.3M | 89.6M | 154.5M | 191M | 200.6M | |
| Non Operating Income Net Other | 6.2M | (23.5M) | 24.7M | (28M) | (25.2M) | (23.9M) | |
| Net Income Applicable To Common Shares | 37.0M | 407.3M | 89.6M | 154.5M | 177.7M | 186.6M | |
| Net Interest Income | (32.0M) | (32.8M) | (25.8M) | (7.1M) | (4.6M) | (4.8M) | |
| Reconciled Depreciation | 7.5M | 8.6M | 10.9M | 15.6M | 20M | 10.8M | |
| Tax Provision | 9.5M | (300.6M) | 11.8M | 59.4M | 60.8M | 63.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.47 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.